A major analysis involving over 1.2 million medical records suggests that GLP-1 receptor agonists, particularly Ozempic and Wegovy, might lower the risk of mental health and addiction issues. The study indicates a modest risk reduction for disorders related to alcohol, cannabis, and opioids, as well as reductions in suicidal thoughts and attempts, schizophrenia, and dementia. While these findings are noteworthy, experts warn against hastily drawing conclusions or altering treatment protocols, given the observational nature of the study and the known side effects of these medications.
The research indicates that popular diabetes and weight loss drugs, like Ozempic and Wegovy, may reduce the risk of various mental and addiction conditions.
Researchers observed a statistically significant reduction in suicidal ideation and self-harm, schizophrenia, and dementia risks, emphasizing the drugs' potential beyond weight loss.
Collection
[
|
...
]